Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it. [More]
Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020. [More]
SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit. [More]
Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified - and ultimately treated. [More]
ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. [More]
Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types. [More]
Molecular classifications of low-grade gliomas proposed

Molecular classifications of low-grade gliomas proposed

Two research teams have independently proposed molecular classification systems for grade II and III glioma based on three tumour markers, with each category displaying distinct clinical features and outcomes. [More]
Discovery may help scientists attack the root of deadliest brain tumors

Discovery may help scientists attack the root of deadliest brain tumors

Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells. [More]
Monteris Medical's NeuroBlate System wins Gold 2015 Medical Design Excellence Award

Monteris Medical's NeuroBlate System wins Gold 2015 Medical Design Excellence Award

Monteris Medical today announced that its NeuroBlate System, a minimally invasive robotic laser thermotherapy tool for treating neurological lesions, has been selected as a gold winning product in the "Surgical Equipment, Instruments, and Supplies" category of the 2015 Medical Design Excellence Awards. [More]
Scientists and clinicians from across the UK come together to address treatment of brain tumors

Scientists and clinicians from across the UK come together to address treatment of brain tumors

In an exciting step forward to finding a cure for brain tumours, which kill more children and adults under the age of 40 than any other cancer, the national charity Brain Tumour Research brought together a group of leading brain tumour scientists and clinicians to help accelerate vital research into this devastating disease. [More]
New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH. [More]
Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex Therapeutics, Inc. today presented positive results from the Company’s randomized, double‐blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII‐positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago. [More]
NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors. [More]
VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer. [More]
Modified poliovirus therapy for glioblastoma works best at a low dosage

Modified poliovirus therapy for glioblastoma works best at a low dosage

A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered. [More]

Small Business Administration presents prestigious Tibbetts Award to Bexion Pharmaceuticals

Bexion Pharmaceuticals LLC announced that the Small Business Administration (SBA) has awarded the Company the prestigious Tibbetts Award, recognizing Bexion as a "Model of Excellence" for the Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. [More]
Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago. [More]
Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses. [More]
Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM). [More]
Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan. [More]
Advertisement
Advertisement